AC Immune makes management appointments
This article was originally published in Scrip
Executive Summary
AC Immune, a Swiss company focused on Alzheimer's disease drug development, has appointed Jean-Fabien Monin chief financial officer and Dr Michael Wagener chief medical director. Mr Monin brings 14 years experience at bioMérieux, where he served as CFO Central Europe. Dr Wagener spent 11 years at Novartis serving as clinical programmedirector for all global Phase I-IV clinical studies in immunology.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.